Remarkably, interest in BCMA continues
But, as Celyad bows out, how do you compete in a field as crowded as this?
Ash 2022 movers – Glycomimetics shakes off its sickle cell past
Meanwhile, there was bad blood between cell therapy players and their investors.
Ash 2022 – fast production fails to cure Car-T's problem
Novartis and Gracell’s two-day manufactured Cars do not solve cell therapy’s biggest bottleneck – yet.
Ash 2022 preview – a new multiple myeloma mechanism makes a splash
Talquetamab gets top billing in Ash’s press programme, but the data raise important issues about the role of targeting GPRC5D.
Asco 2022 movers – cell therapy wins, but it’s not the whole story
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.